EMVision Medical Devices (ASX: $EMV) announcement

EMVision Medical Devices Limited (ASX: $EMV) has successfully established its pilot commercial production line and received the final $1,250,000 non-dilutive cash payment under the Modern Manufacturing Initiative (MMI) grant program. The company was awarded $5 million in non-dilutive funding under the Federal Government's MMI Medical Products Translation stream to establish commercial production of EMVision's emu TM point-of-care brain scanner.

Executive Commentary

The production line, located at EMVision's Macquarie Park premises, has an initial capacity for the build, test, and release of approximately one emu TM brain scanner per week. With modest personnel additions, under its current configuration, the production line is anticipated to have capacity for the build, test, and release of up to 3 emu TM brain scanner devices per week.

Summary of EMVision Medical Devices announcement

EMVision Medical Devices (ASX: $EMV) has achieved a significant milestone by establishing its pilot commercial production line and receiving the final $1,250,000 non-dilutive cash payment under the Modern Manufacturing Initiative (MMI) grant program. The company's vision to transform and improve the timely diagnosis and treatment of stroke and other time-sensitive medical emergencies at the point-of-care is progressing with the development of the emu TM point-of-care brain scanner. With the capacity to build, test, and release up to 3 emu TM brain scanner devices per week, EMVision is poised to make a substantial impact in the medical device industry. The successful establishment of the production line and the grant payment reflect the company's commitment to innovation and advancement in the field of neuroimaging devices.